betamethasone sodium phosphate (SURF-200) / Harrow Health - LARVOL DELTA

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease (clinicaltrials.gov) - P2 | N=139 | Completed | Sponsor: Surface Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed

Adverse events • Trial completion • Dry Eye Disease • Ophthalmology

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: Surface Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2023 ➔ Oct 2022 | Trial primary completion date: Jan 2023 ➔ Oct 2022

Adverse events • Enrollment closed • Trial completion date • Trial primary completion date • Dry Eye Disease • Ophthalmology

A Research Study to See How Well an Eye Drop, SURF-200 (0.02% and 0.04% Betamethasone Sodium Phosphate), Works, What Side Effects There Are, and to Compare it With Vehicle (Placebo) in Subjects Diagnosed With Dry Eye Disease and Experiencing An Episodic Flare-Up (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Surface Pharmaceuticals, Inc.; Trial completion date: Aug 2021 ➔ Mar 2023; Trial primary completion date: Jun 2021 ➔ Jan 2023

Adverse events • Clinical • Trial completion date • Trial primary completion date • Dry Eye Disease • Ophthalmology

A Research Study to See How Well an Eye Drop, SURF-200 (0.02% and 0.04% Betamethasone Sodium Phosphate), Works, What Side Effects There Are, and to Compare it With Vehicle (Placebo) in Subjects Diagnosed With Dry Eye Disease and Experiencing An Episodic Flare-Up (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Surface Pharmaceuticals, Inc.

Adverse events • Clinical • New P2 trial • Dry Eye Disease • Ocular Infections • Ophthalmology